A shocking revelation from within the FDA has sparked intense debate: Are Covid-19 vaccines responsible for child fatalities?
In a confidential memo, Dr. Vinay Prasad, a high-ranking FDA official, made a startling claim: the Covid-19 vaccine may have led to the deaths of 10 children. This assertion is based on an internal analysis that reviewed 96 deaths, attributing 10 of them to the vaccine. Dr. Prasad argues that the risk of death from Covid-19 for healthy young children was already very low, and the vaccine's benefits may not outweigh this risk.
But here's where it gets controversial: Dr. Prasad suggests that the Biden administration's mandates for schools and workplaces pressured children into getting vaccinated, potentially putting them at unnecessary risk. He also compares Covid-19 to other respiratory viruses, stating that its effects are similar to those for which annual vaccines aren't typically required.
Dr. Prasad emphasizes that while many vaccines have proven invaluable, they should be treated like any other medical product. He believes the FDA's current approval process may not adequately assess vaccine safety and effectiveness, potentially leading to harmful outcomes. As a result, the FDA plans to implement a more stringent approval process, demanding more comprehensive safety and value evidence before vaccines reach the market.
This new process will include stricter requirements for vaccines given to pregnant women and pneumonia vaccines, which must demonstrate disease reduction rather than just antibody production. The FDA will also reassess the annual flu vaccine framework and ensure vaccine labels are transparent about safety.
However, this proposed change may significantly delay vaccine approvals, as larger and longer studies may be required. Dr. Prasad invites internal discussion but suggests that dissenting staff should consider resigning.
Interestingly, these views align with those of HHS Secretary Robert F. Kennedy Jr., a known skeptic of vaccine effectiveness. Kennedy has taken controversial actions, such as cutting funding for mRNA vaccine development, removing CDC vaccine advisers, and pushing the CDC to include false claims about autism and vaccines on its website.
Kennedy's handpicked CDC advisory committee will soon discuss changes to the childhood vaccine schedule, including the timing of the hepatitis B vaccine. This vaccine has been recommended for infants at birth for over 30 years, nearly eradicating the disease in US children. Despite no new evidence questioning its safety or effectiveness, the committee is considering delaying the first dose.
And this is the part most people miss: While the FDA's proposed changes aim to enhance safety, they could also slow down the availability of potentially life-saving vaccines. This dilemma raises questions about balancing vaccine accessibility and thorough safety evaluations. What do you think? Is the FDA's proposed approach justified, or does it risk hindering public health progress?
